The secondary subgroup analysis of the single-centre KEYNOTE-001 phase 1 trial¹ by Narek Shaverdian and colleagues, with the accompanying commentary by Dirk De Ruysscher on the association of previous radiotherapy and clinical activity of pembrolizumab in advanced non-small-cell lung cancer (NSCLC), is of great interest and clinical relevance. Progression-free survival and overall survival after pembrolizumab were significantly longer in patients who had received previous radiotherapy than in those who were radiotherapy naive.

中文翻译：

---

为什么在派姆单抗治疗后的生存受到先前放疗的影响？

Narek Shaverdian及其同事对单中心KEYNOTE-001 1期试验¹进行的亚组分析，并附有Dirk De Ruysscher的评论，该评论涉及pembrolizumab在晚期非小细胞肺癌中的先前放疗与临床活性之间的关系。 （NSCLC），具有极大的兴趣和临床意义。接受过先前放疗的患者接受pembrolizumab治疗后的无进展生存期和总生存期明显长于未接受过放疗的患者。